These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 4544565)

  • 1. Impact of virology on modern medicine. Part 1.
    Shortridge KF
    Xianggang Hu Li Za Zhi; 1973 Nov; 15():43-9. PubMed ID: 4544565
    [No Abstract]   [Full Text] [Related]  

  • 2. [Infections with respiratory viruses].
    Popow-Kraupp T
    Ther Umsch; 1994 Aug; 51(8):563-8. PubMed ID: 7940414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
    Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
    Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of modern drugs during mixed circulation of influenza viruses type A].
    Romanov VL; Zosimenko II; Bakeev IuG
    Voen Med Zh; 1982 Feb; (2):34-7. PubMed ID: 7090210
    [No Abstract]   [Full Text] [Related]  

  • 5. Development and characterization of a live attenuated influenza B virus vaccine candidate.
    Seo SU; Byun YH; Lee EY; Jung EJ; Jang YH; Kim HA; Ha SH; Lee KH; Seong BL
    Vaccine; 2008 Feb; 26(7):874-81. PubMed ID: 18207290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
    Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
    Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New viral vaccines.
    Arvin AM; Greenberg HB
    Virology; 2006 Jan; 344(1):240-9. PubMed ID: 16364754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timely topics in microbiology: virology 1968-1969.
    Branson D
    Am J Med Technol; 1970 Apr; 36(4):174-83. PubMed ID: 4909298
    [No Abstract]   [Full Text] [Related]  

  • 10. The Harben lectures, 1957; the experimental approach in preventive medicine. III. Influenza and the common cold.
    HILL AB
    J R Inst Public Health; 1958 Aug; 21(8):209-18. PubMed ID: 13576475
    [No Abstract]   [Full Text] [Related]  

  • 11. Recombinant DNA technology for the preparation of subunit vaccines.
    Bachrach HL
    J Am Vet Med Assoc; 1982 Nov; 181(10):992-9. PubMed ID: 6129235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for developing vaccines against H5N1 influenza A viruses.
    Horimoto T; Kawaoka Y
    Trends Mol Med; 2006 Nov; 12(11):506-14. PubMed ID: 17011235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Influenza and cold].
    Marx HH
    Landarzt; 1968 Aug; 44(24):1129-32. PubMed ID: 5702790
    [No Abstract]   [Full Text] [Related]  

  • 14. [Morbidity of common cold and influenza. Epidemiologic long-time study in the German Army(Bundeswehr). (11 years of retrospection and prognosis)].
    Möbest H; Ritter G
    Munch Med Wochenschr; 1969 Apr; 111(15):870-7. PubMed ID: 5409220
    [No Abstract]   [Full Text] [Related]  

  • 15. Flu for you? The common cold, influenza, and traditional medicine.
    Lee R; Balick MJ
    Explore (NY); 2006 May; 2(3):252-5. PubMed ID: 16781651
    [No Abstract]   [Full Text] [Related]  

  • 16. [Influenza vaccination of Swiss railway and postal personnel, autumn 1970].
    Serati A
    Schweiz Med Wochenschr; 1971 Nov; 101(47):1693-6. PubMed ID: 5143227
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
    Jadhao SJ; Achenbach J; Swayne DE; Donis R; Cox N; Matsuoka Y
    Vaccine; 2008 Mar; 26(14):1742-50. PubMed ID: 18336962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.
    Tamura S; Tanimoto T; Kurata T
    Jpn J Infect Dis; 2005 Aug; 58(4):195-207. PubMed ID: 16116250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant influenza A viruses harboring optimized dicistronic NA segment with an extended native 5' terminal sequence: induction of heterospecific B and T cell responses in mice.
    Vieira Machado A; Naffakh N; Gerbaud S; van der Werf S; Escriou N
    Virology; 2006 Feb; 345(1):73-87. PubMed ID: 16271378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bacteriological paradigm in influenza research in the first half of the twentieth century.
    van Helvoort T
    Hist Philos Life Sci; 1993; 15(1):3-21. PubMed ID: 8310118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.